Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. - Wikidata - awgldk - TriplyDB

Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.

Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.

http://www.wikidata.org/entity/Q36395820

about

Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.Multiple Aspects of Gene Dysregulation in Huntington's Disease Physio-pathological roles of transglutaminase-catalyzed reactions Beyond the glutamine expansion: influence of posttranslational modifications of ataxin-1 in the pathogenesis of spinocerebellar ataxia type 1 Intron-exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer's disease Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases Cellular functions of tissue transglutaminase Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms Treatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/glutamine cell wall structure, and bacterial replication.Identification of two GTP-independent alternatively spliced forms of tissue transglutaminase in human leukocytes, vascular smooth muscle, and endothelial cells.Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability.Neuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin.Transglutaminase regulation of cell function.Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease.Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations.Tissue transglutaminase directly regulates adenylyl cyclase resulting in enhanced cAMP-response element-binding protein (CREB) activation.The selective vulnerability of nerve cells in Huntington's disease.Aberrant calcium signaling by transglutaminase-mediated posttranslational modification of inositol 1,4,5-trisphosphate receptors Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.Type 2 transglutaminase in Huntington's disease: a double-edged sword with clinical potential.Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.Two isoforms of tissue transglutaminase mediate opposing cellular fates.Huntington's Disease and Striatal Signaling.Experimental therapeutics in transgenic mouse models of Huntington's disease.Development of novel therapies for Huntington's disease: hope and challenge.Tissue transglutaminase crosslinks ataxin-1: possible role in SCA1 pathogenesis.Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation.Therapeutics development for triplet repeat expansion diseases.Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiation Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling The Different Conformational States of Tissue Transglutaminase Have Opposing Affects on Cell Viability.Increased levels of gamma-glutamylamines in Huntington disease CSF.Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria.Huntington's disease: progress and potential in the field.Neuroprotection for Huntington's disease: ready, set, slow

P2860

Q24548047-1B13933F-71FF-4BDE-BFE2-A46E50D59D9F Q24605880-DE5025E3-47D9-422D-86E8-F7932C4D481B Q24605961-AAC272DF-C881-4C60-ACFC-5B28F72C516F Q27008548-C63176E3-7EB7-4BB7-B8DD-697405258704 Q28118540-E3F6CCDB-2533-4966-BABE-7EFCF051091D Q28248796-81CE8F98-3E10-4416-A181-5089BEA6CD5F Q28260600-F5F74614-3741-4CA2-A298-C44C12BC54BD Q28592026-4357F0EA-3027-4D59-81A0-FCB1B256B5D6 Q30325785-5CECE6E3-B076-484D-BB3B-69B8D218E338 Q33289840-8B8236EE-0178-4BC2-B94E-74B171E55DE6 Q33536410-B4587339-124E-4C8C-BAEC-2D7A160A6DBC Q33588238-C38EB0EF-8518-47A3-AB92-2D59C0B21B8A Q33707936-1EF54407-D844-4CB9-BBFC-5E183DE47BDE Q33793353-9C103675-05A9-4BC6-B55F-C20FDA4E3ECE Q34077018-F4B597E1-1A11-4514-8BB6-09030F9F633B Q34081469-6E626FF0-7F7A-4698-A575-974F8FED904B Q34196409-9175E9F3-87ED-4077-B36F-C32A7BE915E5 Q34216757-5364B929-EA44-4DB8-9ABE-EEF68C4E8F31 Q34281322-ED21C471-210B-468A-ACE3-25436CB47B53 Q34743269-4C550851-C64D-4FD9-83E8-19E2DA71DABA Q34763209-144BEE6E-E9D4-41E0-BA54-4D450F1558E3 Q34775357-37A5B550-F4ED-4519-9B99-52BFEA8C259C Q34805750-853FFE55-E21D-4FEB-ADA8-090EF0B420AF Q34994779-31FBDF3C-CE1C-46E0-AC76-899FF15DC14D Q35157424-DC9FCBB0-2678-4042-AB24-85AD48F6D52F Q35286098-787CA9EC-C127-4EEE-8186-C2A57AAE0068 Q35752429-37A1FFEB-37FB-4A8B-8216-7D9BF437FA5B Q36016932-D623A1DB-48A0-471F-B43F-2FC2492101A2 Q36227615-0A0DC5D8-438B-47E1-B426-104D212E515F Q36241237-221C0D43-1B9A-4CBC-9ACC-226EF9BDD481 Q36277195-CBC06335-693D-4ABE-83BA-843D99A11F3F Q36342395-A0993DD2-25DF-4E5F-BED0-D2DAC1897ACC Q36358871-22E2F6B1-A43F-47A0-BA93-864490878D45 Q36711191-862061EC-14BE-4525-9058-C8A7433499FD Q36804922-7F9B73D5-51D7-42B3-A2F8-53296FC5E449 Q36884822-BAE60C45-472E-4F4F-85DE-634B9740BA31 Q36952919-8F1FAD01-8D5E-428E-9477-D5A6AD1EDB9D Q37001587-5BE83EDE-8042-463A-A660-44FF865A9983 Q37016096-8AFF828B-CC1E-4B23-97F8-24307AAB4316 Q37131243-4CA84206-3874-4DA6-8993-4924788ABCB6

P2860

Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.

http://www.wikidata.org/entity/Q36395820

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh

1999年學術文章

@zh-hant

name

Transglutaminase aggregates hu ...... ington's disease brain nuclei.

@ast

Transglutaminase aggregates hu ...... ington's disease brain nuclei.

@en

type

label

Transglutaminase aggregates hu ...... ington's disease brain nuclei.

@ast

Transglutaminase aggregates hu ...... ington's disease brain nuclei.

@en

prefLabel

Transglutaminase aggregates hu ...... ington's disease brain nuclei.

@ast

Transglutaminase aggregates hu ...... ington's disease brain nuclei.

@en

P1433

Q36395820-ED1F842D-7CEB-4C69-89A0-4AFC8A65914C

P1476

Q36395820-6FE832C5-9C75-408F-8C6E-046C1C165606

P2093

Q36395820-2765FB02-808E-402C-A118-5F2F96FB9FA6

Q36395820-36F3A7C0-2D56-4A27-98B4-B03A15E2CF82

Q36395820-511F4C62-8788-4831-837C-23DE356ECCCC

Q36395820-5EDCE1D2-049C-4D6C-ACD7-E24FDD860CF9

Q36395820-D8E54EF6-EA89-42C3-91A3-39BAA9461D16

Q36395820-DDE1099D-99D5-45E1-9D69-734CBDD971E3

P2860

Q36395820-078D2A6D-96AE-44D8-8426-B10B509A5EEF

Q36395820-0C9AB469-BDDC-4F8B-B1C8-4F705455A797

Q36395820-0FA17B8E-0454-4074-8164-C1F713D78731

Q36395820-19194379-30F5-468C-AB80-672184EB8255

Q36395820-2C82EA95-11F7-4A2D-834D-3446DBC9CCDA

Q36395820-30F81E97-54BB-443E-8E9F-355F5D27AE51

Q36395820-32A0BD3C-2197-43B1-9E5B-069FBB0D3FED

Q36395820-44C54866-05E8-4CE5-8A82-AF06C6457F1A

Q36395820-67C2BCD4-9AB8-477F-B4F9-52B9B5AC7EF5

Q36395820-6E2424F3-6408-43A6-AD50-64E940246D83

P304

Q36395820-9FDD0411-8302-490E-A35A-BB38BCBB3018

P31

Q36395820-0A746D34-8569-4EDF-B266-2F0E130E1011

P356

Q36395820-2D490D20-BBD1-434A-BAD6-D12F15BC290F

P407

Q36395820-A8C0AA92-41D7-4FDD-A537-426CF674A752

P433

Q36395820-6E74C663-EAB4-41CD-BB80-FF32D35B5D26

P478

Q36395820-6BB4BE30-8A25-4E10-9112-CB0CB08B256C

P50

Q36395820-BBC3F9B4-3BA5-4AC8-AC8C-9456DC7E7C02

P577

Q36395820-0ECA604B-8B8B-4F21-81D2-9455C52A2B90

P5875

Q36395820-DC6293C7-5FCE-4727-822E-C92F4CE8CE8B

P698

Q36395820-403A2FF2-7AC8-402A-9E68-EE2D05A905BB

P921

Q36395820-821EFA05-E1C8-4CFA-B175-5F0FF9B48FC8

P932

Q36395820-E98F3091-B17F-4972-B27F-F41C5BF18A2F

P356

PNAS.96.13.7388

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Transglutaminase aggregates hu ...... ington's disease brain nuclei.

@en

P2093

D L Price

http://www.w3.org/2001/XMLSchema#string

H Garren

http://www.w3.org/2001/XMLSchema#string

H Slunt

http://www.w3.org/2001/XMLSchema#string

L Steinman

http://www.w3.org/2001/XMLSchema#string

M V Karpuj

http://www.w3.org/2001/XMLSchema#string

M W Becher

http://www.w3.org/2001/XMLSchema#string

P2860

Rapid and phosphoinositol-dependent binding of the SWI/SNF-like BAF complex to chromatin after T lymphocyte receptor signaling

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative diseases.

Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases.

Neurodegenerative diseases and transglutaminase.

Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts).

Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates.

Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract.

The neuropathology of CAG repeat diseases: review and update of genetic and molecular features.

P304

7388-7393

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.96.13.7388

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

James F. Gusella

P577

1999-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235606420

http://www.w3.org/2001/XMLSchema#string

P698

10377424

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

22095

http://www.w3.org/2001/XMLSchema#string